TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
(13 pages) 2011 in The Lancet Oncology, vol. 12, pp. 527-39
DOI: https://doi.org/10.1016/S1470-2045(11)70094-8
Research output: Contribution to Journal › Article (Published)
The benefits and harms of breast cancer screening: an independent review
(9 pages) 17 Nov 2012 in The Lancet, vol. 380, pp. 1778-1786
DOI: https://doi.org/10.1016/S0140-6736(12)61611-0
Research output: Contribution to Journal › Literature review (Published)
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
Mar 2013 in The Lancet Oncology, vol. 14, pp. 244–248
DOI: https://doi.org/10.1016/S1470-2045(13)70017-2
Research output: Contribution to Journal › Article (Published)
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
(10 pages) 1 Sep 2013 in The Lancet Oncology, vol. 14, pp. 933-942
DOI: https://doi.org/10.1016/S1470-2045(13)70335-8
Research output: Contribution to Journal › Article (Published)